Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections. Its lead program combines bemnifosbuvir, a nucleotide polymerase inhibitor, with ruzasvir, an NS5A inhibitor, in late-stage development for hepatitis C. The company also advances earlier antiviral candidates and builds on a nucleoside/nucleotide chemistry platform rather than commercialized marketed products today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -34.3 | — |
| Q2 2025 | 0 | — | -37.2 | — |
| Q3 2025 | 0 | — | -42 | — |
| Q4 2025 | 0 | — | -44.9 | — |
| Q1 2026 | 0 | — | -45.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: The Metals Royalty Company Inc. (TMCR), Weyco Group, Inc. (WEYS), Eupraxia Pharmaceuticals Inc. (EPRX), Plumas Bancorp (PLBC), FRP Holdings, Inc. (FRPH), Xerox Holdings Corporation (XRX)